Proactiveinvestors Australia Elixinol Global Ltd https://www.proactiveinvestors.com.au Proactiveinvestors Australia Elixinol Global Ltd RSS feed en Sun, 16 Jun 2019 08:47:25 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Elixinol Global purchases site for state-of-the-art Australian manufacturing facility ]]> https://www.proactiveinvestors.com.au/companies/news/214138/elixinol-global-purchases-site-for-state-of-the-art-australian-manufacturing-facility-214138.html Elixinol Global Ltd (ASX:EXL) has further developed its Australian medicinal cannabis business with the purchase of a property for an integrated cultivation and manufacturing facility.

The property is a unique 60-acre lot with the first stage of planning involving a 5,000-metre footprint on a secured 4.9-acre block within the area.

READ: Elixinol Global attracts $40 million to accelerate international growth initiatives

Elixinol Global CEO Paul Benhaim said: “We are confident that our expertise in creating high-quality cannabis formulations in the USA under our Elixinol brand will position Nunyara to take a leading role in the establishment of the Australian medical cannabis industry.

“Our purchase of this unique property is simply another step in that process.”

Capacity to expand

The company will have the capacity to expand the proposed greenhouses as well as in-built expansion capacity within the GMP-certified pharmaceutical-grade manufacturing facility.

The Australian subsidiary has also been changed its name from Elixinol Australia Pty Ltd to Nunyara Pharma Pty Ltd (Nunyara).

 

 

Nunyara is an Australian indigenous word meaning ‘to be made well again’.

The name change is designed to differentiate the medical cannabis activities of Nunyara from those of EXL’S Colorado-based business, Elixinol, which is focused on hemp-derived CBC dietary supplements and fast-moving consumer goods.

Nunyara was formed in 2014 to participate in the emerging Australian medicinal cannabis market and submitted licence applications for cultivation and manufacture to the Office of Drug Control in early 2018.

These applications are pending approval.

- Jessica Cummins 

]]>
Wed, 06 Feb 2019 22:45:00 +1100 https://www.proactiveinvestors.com.au/companies/news/214138/elixinol-global-purchases-site-for-state-of-the-art-australian-manufacturing-facility-214138.html
<![CDATA[News - Elixinol Global attracts $40 million to accelerate international growth initiatives ]]> https://www.proactiveinvestors.com.au/companies/news/205933/elixinol-global-attracts-40-million-to-accelerate-international-growth-initiatives-205933.html Elixinol Global Ltd (ASX:EXL) (OTCMKTS:ELLXF) has successfully completed a share placement to domestic and international institutional and sophisticated investors raising $40 million at $1.85 per share.

The group’s portfolio comprises three main divisions: Elixinol USA focused on dietary supplements; Hemp Foods Australia selling food products; and Elixinol Australia, the new start-up focused on medicinal cannabis.

Los Angeles, why is hemp CBD what all your friends are talking about? Find out for yourself! we’ll be at Cannabis World Congress Los Angeles today! Will we see you there? #CWCBExpo @CWCBExpo pic.twitter.com/mcbrHz2uTO

— ElixinolCBD (@ElixinolCBD) September 27, 2018

The company listed on the ASX in January this year and raised about $20 million from an oversubscribed initial public offer.

Elixinol chief executive officer Paul Benhaim said: “The global cannabis market is growing at a rapid rate and Elixinol Global recognises the need to move quickly to leverage the opportunity around the business.

“This funding ensures we can seize the market opportunities in front of us, and in doing so, propel the business toward its next phase of growth.”

 

Elixinol will apply the funds towards increasing the capacity of its hemp-derived CBD (cannabidiol) production facility in the US to prepare for increasing levels of demand.

The company will also ramp up its sales force and marketing efforts in the US and Europe.

The new funding will also provide Elixinol with additional working capital to support its growth, pursue strategic investment opportunities and construct its Australian medicinal cannabis facility, upon receipt of a medicinal cannabis license from the Office of Drug Control.

Benhaim added: “We are grateful for the support from existing and new investors who participated in this capital raising in recognition of our world-class brand that continues to drive revenue growth and profitability for Elixinol Global.”

]]>
Fri, 28 Sep 2018 14:51:00 +1000 https://www.proactiveinvestors.com.au/companies/news/205933/elixinol-global-attracts-40-million-to-accelerate-international-growth-initiatives-205933.html
<![CDATA[Media files - Elixinol Global 'only company in the sector to list a profit' ]]> https://www.proactiveinvestors.com.au/companies/stocktube/10388/elixinol-global-only-company-in-the-sector-to-list-a-profit--10388.html Thu, 06 Sep 2018 22:27:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/10388/elixinol-global-only-company-in-the-sector-to-list-a-profit--10388.html <![CDATA[News - Elixinol Global eyes new cannabis opportunities after raising $20 million ]]> https://www.proactiveinvestors.com.au/companies/news/189566/elixinol-global-eyes-new-cannabis-opportunities-after-raising-20-million-189566.html Elixinol Global Ltd (ASX:EXL) is the latest cannabis company to be admitted to the ASX and will commence trading from Monday, 8 January 2018.

The company has raised $20 million via an initial public offer of shares at $1.00 each.

Elixinol is already established in the U.S., where it manufactures and distributes industrial hemp-based nutraceuticals, dietary supplements and skincare products.

The company also owns Hemp Foods Australia, which was founded in 1999 and manufactures and distributes industrial hemp-derived products in Australia.

Elixinol’s strategy is to capitalise on the opportunities provided by being invested in a range of emerging cannabis related sectors including hemp, CBD (cannabidiol) nutraceuticals and wellness products.

New favourable cannabis regulation in Australia

Favourable legislative changes in Australia mean that Hemp Foods Australia is now permitted to sell hemp food products, offering the potential to expand distribution channels and grow its market.

In the medicinal cannabis sector, new legislation has been passed in Australia to enable the cultivation of cannabis for medicinal and related research purposes.

Earlier this week, the Australian federal government decided to allow export of medicinal cannabis in a bid to strengthen supply amid growing demand domestically and worldwide.

Elixinol US is an expert in CBD derived products

Subject to obtaining the requisite licences, Elixinol Australia can leverage Elixinol US’s expertise in extraction and processing of CBD derived products.

Each of the businesses within the Elixinol Group was co-founded by Paul Benhaim, a pioneer in the Australian industrial hemp sector.

Benhaim has over 25 years’ of experience in industrial hemp legislation, cultivation, manufacturing, production, sales and marketing in Europe, North America and Australasia.

]]>
Fri, 05 Jan 2018 16:32:00 +1100 https://www.proactiveinvestors.com.au/companies/news/189566/elixinol-global-eyes-new-cannabis-opportunities-after-raising-20-million-189566.html